WEST LAFAYETTE, Ind., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT ), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that the company will host a conference call on Tuesday, Nov. 5, at 4:30 p.m. EST to discuss its third quarter 2013 financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investor Relations section of the Company's website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
A replay of the call will be available beginning at 7:30 p.m. EST on Nov. 5, until midnight EST on Nov. 11, 2013. To access the replay, please dial (855) 859-2056 (U.S./Canada) or (404) 537-3406(International) and reference the conference 83218992. Additionally, the webcast will be recorded and available on the Company's website for two weeks following the call.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com .
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292, Tony Russo, Ph.D., Russo Partners, (212) 845-4251,
